Deloitte China has recently announced its 2025 Technology Fast Program lists. META stood out among numerous outstanding applicants, earning a place on the **2025 Deloitte China Seed Award for Pharmaceutical & Health** list, recognized for its pioneering innovation in immunometabolism, substantial R&D translational capabilities, and significant technological potential.

The Deloitte Technology Fast Program was founded in 1995 in Silicon Valley and entered China in 2005. Held annually in dozens of countries and regions, it is recognized as a benchmark for high-growth companies worldwide. Previous winners include Tencent, Alibaba, JD.com, ByteDance, SMIC, WuXi AppTec, Mindray, Microsoft, Apple, NVIDIA, and Tesla. This year, the Deloitte China Technology Fast Program presented five awards, including the Pharmaceutical & Health Seed Award.

Founded in 2021, META has built an innovative drug pipeline covering multiple autoimmune and metabolic disease areas. MP-5342, its lead asset, is the world’s first oral small molecule inhibitor of lactate dehydrogenase (LDH) originating from a novel biological theory. In animal models of multiple autoimmune diseases, particularly inflammatory bowel disease (IBD), MP-5342 has demonstrated a superior efficacy and safety balance compared to current standards of care, with broad-spectrum therapeutic potential that could rival Humira as a breakthrough therapy.

This recognition reflects the confidence of capital markets and professional institutions in META’s growth potential. Moving forward, META will continue to steadily advance its pipeline R&D, committed to delivering clinically meaningful breakthrough therapies for patients.